Schizophrenia Tied to Increased Risk for Later Parkinson Disease
MONDAY, Feb. 1, 2021 -- Schizophrenia spectrum disorder increases the risk for Parkinson disease (PD) later in life, according to a study published online Jan. 6 in Movement Disorders.
Tomi Kuusimäki, M.D., from Turku University Hospital in Finland, and colleagues investigated the risk for PD after a diagnosis of a schizophrenia spectrum disorder. The analysis included 3,045 patients with a confirmed PD diagnosis (2004 to 2019).
The researchers found that the prevalence of earlier schizophrenia spectrum disorder was 0.76 percent in PD patients in regional data and 1.50 percent in nationwide data, while in age-matched controls, the prevalence of schizophrenia spectrum disorder in the regional and national data was 0.16 and 1.31 percent, respectively. Following a schizophrenia diagnosis, the odds ratio for PD was 4.63 in the regional data and 1.17 in the national data.
"The occurrence of PD and schizophrenia in the same person has been considered rare because these diseases are associated with opposite alterations in the brain's dopamine system," Kuusimäki said in a statement. "Our study changes this prevailing conception."
© 2021 HealthDay. All rights reserved.
Posted: February 2021
Read this next
THURSDAY, Feb. 18, 2021 -- Users of terazosin, doxazosin, or alfuzosin are at lower risk for developing Parkinson disease (PD) compared with users of tamsulosin, according to a...
WEDNESDAY, Feb. 17, 2021 -- Emergency department visits for mental health, substance use, and violence decreased in the early days of the COVID-19 pandemic, according to a study...
WEDNESDAY, Feb. 10, 2021 -- Parkinson disease (PD) symptoms and management practices were markedly affected by COVID-19, according to a study published online Jan. 21 in npj...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.